With its inherent advantages, X-ray powder diffraction (XRPD) has been widely used in the qualitative and quantitative studies of drug solid states. Research and exploration of XRPD are present throughout all stages of drug solid-state research.
QbD (Quality by Design) is a systematic pharmaceutical development concept that emphasizes designing the quality of the product throughout the entire drug development and production process. Medicilon Cloud Lecture Hall invites Dr. Binbin Liu to share his practical experience and insights on applying the QbD concept in pharmaceutical formulation development. Let’s take a look at Dr. Liu’s Q&A session.
Genotoxic impurities refer to compounds or substances that may cause damage to genetic material (DNA or RNA) in biological cells.
The residue of solvent in APIs is one of the key issues to be mindful of during drug manufacturing. Medicilon Cloud Lecture invites the head of the Process Analysis Department, Maodun Xie to share with us the challenges and solutions regarding solvent residue in APIs during preclinical operations.
The stability testing of APIs is a crucial aspect of drug production, as it directly impacts the quality and efficacy of the medications.
Currently, cardiovascular disease (CVD) has become an important topic in the global public health. According to the “2022 Report on Cardiovascular Health and Diseases in China,” the number of cardiovascular disease patients in China is as high as 330 million, including 245 million hypertensive patients, 13 million stroke patients, 11.39 million coronary heart disease patients, and 8.9 million heart failure patients.
In vitro release testing (IVRT) and in vitro permeation testing (IVPT) are key pharmaceutical techniques for evaluating the pharmaceutical research of topical dermatological formulations.
In the research and development of new drugs, ion chromatography technology is widely used in drug ingredient analysis, content detection and impurity control. Ion chromatography technology makes up for the shortcomings of conventional chromatography technology in drug research and development, providing reliable technical support for drug quality control and drug safety evaluation.
Medicilon’s DMPK&BA department offers our clients a broad spectrum of high quality services in the areas of in vitro ADMET, in vivo PK & BA, and non-GLP Tox services for both small and large molecule drugs, such as proteins, antibodies, oliogonucleotides, ADC and new modalities.
In Medicilon, we exploit drug exposure induction approach for drug resistant model development purpose.
Address: 1 Broadway, Cambridge, MA02142 (America)
Tel: +1(626)986-9880(U.S. – West Coast)
Address: Allia Future Business Centre Kings Hedges Road
Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954 (Europe)
Email: marketing@medicilon.com
Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul,
06643 South Korea
Tel: +82 70-8269-5849
Address: No.585 Chuanda Road, Pudong New Area, Shanghai
(Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
